Home › Compare › LNNNY vs ABBV
LNNNY yields 6666.67% · ABBV yields 3.06%● Live data
📍 LNNNY pulled ahead of the other in Year 1
Combined, LNNNY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LNNNY + ABBV for your $10,000?
LEONI AG, together with its subsidiaries, provides products, solutions, and services for energy and data management in the automotive sector and other industries worldwide. It operates in two divisions, Wiring Systems, and Wire & Cable Solutions. The Wiring Systems division provides complete wiring systems and customized cable harnesses for the motor vehicle industry. Its products and services comprise cable harnesses through to integrated wiring systems, high-voltage wiring systems for hybrid and electric vehicles, energy distribution components, and special connectors, as well as related services. The Wire & Cable Solutions division manufactures and sells wire and cable systems; and provides energy transmission and data management system solutions. This segment offers a range of products and services, such as wires, strands, optical fibers, standardized cables, special cables, and fully assembled systems, as well as related services for customers in the automotive, capital goods, medical technology, telecommunications, energy, and infrastructure industries. The company was formerly known as Leonische Drahtwerke AG and changed its name to LEONI AG in 1999. The company was founded in 1569 and is headquartered in Nuremberg, Germany.
Full LNNNY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.